Your browser doesn't support javascript.
loading
Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn's disease.
Hanzel, Jurij; Kozelj, Matic; Spes Hlastec, Ana; Kurent, Tina; Sever, Nejc; Zdovc, Jurij; Smrekar, Natasa; Novak, Gregor; Stabuc, Borut; Grabnar, Iztok; Drobne, David.
Afiliação
  • Hanzel J; Department of Gastroenterology, University Medical Centre Ljubljana.
  • Kozelj M; Department of Internal Medicine, Medical Faculty, University of Ljubljana, Ljubljana.
  • Spes Hlastec A; Department of Gastroenterology, University Medical Centre Ljubljana.
  • Kurent T; Department of Gastroenterology, Celje General Hospital, Celje.
  • Sever N; Department of Gastroenterology, University Medical Centre Ljubljana.
  • Zdovc J; Department of Gastroenterology, University Medical Centre Ljubljana.
  • Smrekar N; Chair of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
  • Novak G; Department of Gastroenterology, University Medical Centre Ljubljana.
  • Stabuc B; Department of Gastroenterology, University Medical Centre Ljubljana.
  • Grabnar I; Department of Internal Medicine, Medical Faculty, University of Ljubljana, Ljubljana.
  • Drobne D; Department of Gastroenterology, University Medical Centre Ljubljana.
Eur J Gastroenterol Hepatol ; 33(1S Suppl 1): e831-e836, 2021 12 01.
Article em En | MEDLINE | ID: mdl-34402470

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Crohn / Ustekinumab Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Crohn / Ustekinumab Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article